Close

Halozyme Therapeutics (HALO): Reiterate Overweight After KOL Discussions - Piper Jaffray

June 23, 2016 6:59 AM EDT Send to a Friend
Piper Jaffray analyst, Charles Duncan, reviewed Halozyme Therapeutics's (NASDAQ: HALO) Halozyme Phase II PEGPH20 data at ASCO'16, and hosted a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login